BofA/Merrill Lynch Downgrades Achillion Pharmaceuticals (ACHN) to Underperform

September 30, 2013 6:45 AM EDT Send to a Friend
BofA/Merrill Lynch downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login